The Medicines Company (NasdaqGS:MDCO) will look for acquisitions. Medicines Company has completed a Follow-on Equity Offering in the amount of $150.000015 million. We intend to use the net proceeds from this offering to fund our development of inclisiran and for general corporate purposes. General corporate purposes may include the acquisition of complementary products, technologies or businesses, repayment and refinancing of debt, pre-commercial activities, working capital and capital expenditures.